Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: A trial from the University of Rochester Cancer Center Community Clinical Oncology Program
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background Sleep problems are a frequent distressing symptom in cancer patients, yet little is known about their treatment. Sleep problems and depression frequently co-occur, leading healthcare professionals to treat depression with the expectation that sleep problems will also improve. The purpose of this study was to compare the effect of paroxetine to placebo on sleep problems via a secondary data analysis of a RCT designed to compare the effects of paroxetine to placebo on fatigue in cancer patients undergoing chemotherapy. A previously published report found a significant effect of paroxetine on depression in this cohort. Methods A total of 426 patients were randomized following Cycle 2 of chemotherapy to receive either 20 mg of paroxetine or placebo. Sleep problems were assessed using questions from the Hamilton Depression Inventory three times during chemotherapy. Results A total of 217 patients received paroxetine and 209 received placebo. Significantly fewer patients taking paroxetine reported sleep problems compared to patients on placebo (Paroxetine 79% versus Placebo 88%; p < 0.05). These differences remained significant even after controlling for baseline sleep problems and depression (p < 0.05). Conclusion Paroxetine had a significant benefit on sleep problems in both depressed and non-depressed cancer patients. However, rates of sleep problems remained high even among those effectively treated for depression with paroxetine. There is a need to develop and deliver sleep-specific interventions to effectively treat sleep-related side effects of cancer treatments. These findings suggest that sleep problems and depression are prevalent and co-morbid. Cancer progression, its response to treatment, and overall patient survival are intricately linked to host factors, such as inflammatory response and circadian rhythms, including sleep/wake cycles. Sleep problems and depression are modifiable host factors that can influence inflammation and impact cancer progression and quality of life. Future research should focus on discovering the pathogenesis of sleep dysregulation and depression in cancer so that better treatment approaches can be developed to ameliorate these symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Regan, M. M., Price, N. J., Dinges, D. F., & Mullington, J. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.050 · Cited by 1,195 · cited 1×
“Moreover, some data show that sleep problems and sleep loss are associated with dysregulated immune function [10–15].”
BackgroundDo stress-related psychosocial factors contribute to cancer incidence and survival?
Chida, Y., Hamer, M., Wardle, J., & Steptoe, A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1134 · Cited by 1,072 · cited 1×
“Several epidemiological and experimental studies suggest that severe and chronic depression in cancer patients might influence disease progression [23–25].”
BackgroundThe influence of bio-behavioural factors on tumour biology: pathways and mechanisms
Antoni, M. H., Lutgendorf, S. K., Cole, S. W., Dhabhar, F. S., Sephton, S. E., McDonald, P. G., Stefanek, M., & Sood, A. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1820 · Cited by 981
Night Shift Work, Light at Night, and Risk of Breast Cancer
Davis, S., Mirick, D. K., & Stevens, R. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.20.1557 · Cited by 930
Cancer-related fatigue: the scale of the problem
Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., Jean-Pierre, P., & Morrow, G. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-s1-4 · Cited by 895
Self-citationNonpharmacologic Treatment of Chronic Insomnia
Morin, C. M., Hauri, P. J., Espie, C. A., Spielman, A. J., Buysse, D. J., & Bootzin, R. R. (1999) · Sleep · doi:10.1093/sleep/22.8.1134 · Cited by 888
Depression and cancer: mechanisms and disease progression
Spiegel, D., & Giese-Davis, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00566-3 · Cited by 874 · cited 1×
“Nearly 25% of cancer patients meet criteria for major depression, with an additional 30% reporting symptoms [22].”
BackgroundInsomnia in the Context of Cancer: A Review of a Neglected Problem
Savard, J., & Morin, C. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.895 · Cited by 861
Prevalence, burden, and treatment of insomnia in primary care
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.10.1417 · Cited by 694 · cited 1×
“In the general population, sleep problems are associated with significant impairments in quality of life [7], almost a two-fold increase in accidents [8], increased days spent in bed, and decreased activity [9].”
BackgroundPalesh, O. G., Roscoe, J. A., Mustian, K. M., Roth, T., Savard, J., Ancoli-Israel, S., Heckler, C., Purnell, J. Q., Janelsins, M. C., & Morrow, G. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.5011 · Cited by 557
Self-citation
Cited by
Multicenter, Randomized Controlled Trial of Yoga for Sleep Quality Among Cancer Survivors
Mustian, K. M., Sprod, L. K., Janelsins, M., Peppone, L. J., Palesh, O. G., Chandwani, K., Reddy, P. S., Melnik, M. K., Heckler, C., & Morrow, G. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7707 · Cited by 282
“To be eligible, survivors must (1) have a confirmed diagnosis of cancer; (2) have completed treatment for cancer; (3) have sleep disturbance (indicated by a response of 3 on a clinical symptom inventory by using an 11-point scale anchored by 0 [no sleep disturbance] and 10 [worst possible sleep disturbance]); (4) be a…”
BackgroundSelf-citationAntidepressants for the treatment of depression in people with cancer
Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C., & Hotopf, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub3 · Cited by 158
Antidepressants for the treatment of depression in people with cancer
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73
Metadata
- Authors
- Palesh, O. G., Mustian, K. M., Peppone, L. J., Janelsins, M., Sprod, L. K., Kesler, S., Innominato, P. F., Roth, T., Manber, R., Heckler, C., Fiscella, K., & Morrow, G. R.
- Venue
- Sleep Medicine
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 13
- Issue
- 9
- Pages
- 1184-1190
- ISSN
- 1389-9457 (ISSN-L)
- OpenAlex
- W1999672434
- Cited by
- 36
- References
- 18
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: A trial from the University of Rochester Cancer Center Community Clinical Oncology Program. https://app.cochat.ai/papers/10.1016/j.sleep.2012.06.001
- The paper
- Palesh, O. G., Mustian, K. M., Peppone, L. J., Janelsins, M., Sprod, L. K., Kesler, S., Innominato, P. F., Roth, T., Manber, R., Heckler, C., Fiscella, K., & Morrow, G. R. (2012). Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: A trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Medicine. https://doi.org/10.1016/j.sleep.2012.06.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.